Bonjour, non beaucoup moins, le dernier chiffre que j'ai vu c'est 12x moins contagieux (car même quand ils sont asymptomatiques ils ont une charge virale moindre).
Non ça n'est pas le cas, voir par exemple cette étude sortie hier du PHE (UK) :Justement, dans les catégories les plus à risques, si j'en crois ce que j'ai entendu hier à la radio par un des membres du conseil scientifique, en Angleterre qui est le pays où l'on peut le mieux s'appuyer pour prédire ce qui pourrait arriver en France, vu la pression du variant chez eux), les chiffes d'hospitalisation (donc réa aussi) augmentent pour les plus fragiles, et c'est pour cela que le conseil préconise une troisième dose pour les plus vulnérables (personnes âgées, à comorbidités, ect).
https://khub.net/documents/135939561...f-5dc796f5a91fBackground
Covid-19 vaccines have been found to be highly effective in general population cohorts, however,
data on effectiveness among individuals with clinical conditions that place them at increased risk of
severe disease is limited
Findings
There was no notable reduction in S-antibody positivity or titres in most clinical risk groups. The only
clinical risk group with significantly reduced S-antibody response after one and 2 doses was the
immunocompromised group who had a 68% (95%CI: 43 to 82%) reduction in the geometric mean
titre after 2 doses. Reduced vaccine effectiveness against clinical disease was also noted in the
immunosuppressed group after one dose, however, after a second dose of either vaccine, high levels
of effectiveness were seen (Pfizer: 73.0%, 95%CI 33.9 to 89.0%; AstraZeneca 74.6%, 95%CI 18.7 to
92.1%).
Interpretation
In most clinical risk groups, immune response to vaccination is maintained and high levels of VE are
seen with both the Pfizer and AstraZeneca vaccines. Reduced antibody response and vaccine
effectiveness were seen after one dose of vaccine among the immunosuppressed group, however,
after a second dose there is only a small and non-significant reduction in vaccine effectiveness.
These findings would support maximising coverage with two doses in immunosuppressed
individuals.
-----